PubMed Health⌕ Search

Biomedical subjects

R E Varner

Publications and source records attributed to R E Varner.

24 records · Page 2Linked to original sources

Hyperandrogenic state associated with a mucinous cystadenoma.

A case of mucinous cystadenoma associated with androgen secretion is presented to add to the growing body of literature concerning hormone secretion by ovarian neoplasms regarded as "nonfunctional." The theorized mechanisms of hormone production in these tumors also are reviewed.

Aged↗

Cefotetan versus cefoxitin as prophylaxis in hysterectomy.

Seventy hospitalized women were entered into an open, randomized, parallel study of antimicrobial prophylaxis for abdominal and vaginal hysterectomy with the use of either cefotetan, a new long-acting cephalosporin, or cefoxitin. Ninety-four percent of cefotetan recipients and 83% of cefoxitin recipients did not develop clinical signs or symptoms of infection. The satisfactory bacteriologic response rates were significantly different: 91% satisfactory (43 of 47 patients) for cefotetan and 74% satisfactory (17 of 23 patients) for cefoxitin. The two treatment groups demonstrated no significant differences in postoperative temperature changes, duration of hospitalization, or grading of surgical wounds. Neither drug was associated with significant side effects.

Adult↗

Müllerian dysgenesis.

The multifaceted syndrome of müllerian dysgenesis appears to represent a defect in mesodermal organization and is often associated with renal and skeletal anomalies. This report discusses the embryology, multifactorial etiology, clinical presentation and management of the syndrome from a historical standpoint and details our experience with 35 affected patients. Both Frank dilatation and McIndoe vaginoplasty appear to be acceptable means of therapy. The therapeutic success depends to a large extent on the psychosocial adaptation of the patient.

Abnormalities, Multiple↗

Force production decay rate in Alastik modules.

The production and decay of forces produced by Alastik modules was studied under conditions simulating clinical usage over time period of 2 hr to 4 weeks. Force decay was moderate and all Kx modules tested produced approximately 1 lb of force at the end of the 4-week test period. Therefore, from a clinical standpoint, modules need not be changed more frequently than once every 4 weeks.

Activator Appliances↗